MiMedx Group (MDXG) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

MiMedx Group

NasdaqCM•Healthcare•Biotechnology

$3.92-0.06(-0.01%)Market open

Market Cap

$478.44M

P/S

1.6x

P/B

2.3x

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.

How this company scores

AverageMetricSide Score: 46/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Growth (5/25).

Profitability11/25

Growth5/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality15/25

Strengths

Long cash runwayInterest easily coveredCash-backed earningsNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 92.7x5y range 9.8x – 195.5x

Currently above its 12-quarter median.

P/S · 1.6x5y range 1.2x – 4.0x

Currently below its 20-quarter median.

P/B · 2.3x5y range 2.3x – 8109.8x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 206.6% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Price & Volume

Market Cap $478.44M

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $303.73M
Q. Revenue: $62.28M
TTM EBITDA: $-8.92M
TTM Op. Income: $-25.14M
Q. Op. Income: $-11.70M
TTM Net Income: $-19.19M
Q. Net Income: $-8.68M
EPS: $-0.06
Shares Out.: $145.87M

$303.73M in TTM revenue declined 22.8% YoY, reaching $62.28M last quarter. TTM EBITDA of $-8.92M and TTM operating income of $-25.14M show growth is flowing through to the bottom line. However, net income is negative at $19.19M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 3 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 79.8%
EBITDA Margin: -17.9%
Op. Margin: -18.8%
Net Margin: -13.9%

Op. margin of -18.8% is down 38.3% YoY — costs are rising relative to revenue. Net margin at -13.9% and gross margin of 79.8% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 196% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 1.6x
P/B Ratio: 2.3x

P/S of 1.6x and P/B of 2.3x. P/S is low relative to typical market levels. Over the past year, P/E is up 230% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $264.55M
Cash: $120.79M
Long-Term Debt: N/A
Book Value: $211.08M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $3.92M
TTM Free Cash Flow: $19.12M
FCF Margin: 6.3%
FCF / Net Income: -1.0

TTM FCF of $19.12M on $3.92M in operating cash flow. The FCF / Net Income ratio of -1.0x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has fallen for 3 consecutive quarters — a weakening trend.